Top Page
dorsaVi Limited
(Sydney:DVL)
dorsaVi Limited (DVL) vs. iShares MSCI Australia ETF (EWA)
dorsaVi Limited Business Overview & Revenue Model
dorsaVi Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.13M | 1.13M | 1.30M | 1.75M | 2.35M | 1.87M |
| Gross Profit | 971.82K | 971.82K | 1.18M | -798.43K | -1.45M | -1.74M |
| EBITDA | -1.82M | -1.82M | -1.60M | -1.88M | -1.53M | -2.29M |
| Net Income | -1.52M | -1.52M | -1.25M | -1.82M | -1.54M | -2.41M |
Balance Sheet | ||||||
| Total Assets | 3.97M | 3.97M | 2.18M | 2.69M | 3.36M | 5.42M |
| Cash, Cash Equivalents and Short-Term Investments | 2.29M | 2.29M | 478.10K | 878.72K | 449.70K | 2.80M |
| Total Debt | 156.89K | 156.89K | 190.17K | 321.85K | 1.18M | 1.18M |
| Total Liabilities | 1.14M | 1.14M | 1.16M | 1.01M | 2.13M | 2.95M |
| Stockholders Equity | 2.84M | 2.84M | 1.02M | 1.68M | 1.22M | 2.48M |
Cash Flow | ||||||
| Free Cash Flow | -956.83K | -956.83K | -622.08K | -1.02M | -2.25M | -2.36M |
| Operating Cash Flow | -956.83K | -956.83K | -600.90K | -967.41K | -2.15M | -2.27M |
| Investing Cash Flow | -304.00K | -304.00K | -21.18K | -51.65K | -100.34K | -85.41K |
| Financing Cash Flow | 3.08M | 3.08M | 227.06K | 1.45M | -92.25K | 3.47M |
dorsaVi Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
41 Neutral | AU$10.13M | -0.32 | ― | ― | -51.64% | -21.74% | |
40 Underperform | AU$3.27M | -0.90 | ― | ― | -4.86% | 64.36% | |
39 Underperform | AU$38.26M | -17.00 | -78.66% | ― | -13.40% | 4.76% | |
38 Underperform | AU$6.91M | -0.52 | -135.89% | ― | -21.60% | -657.00% | |
37 Underperform | AU$5.29M | -0.76 | -283.40% | ― | -74.76% | 42.11% |
dorsaVi Limited Corporate Events
DorsaVi Limited has announced significant progress in its RRAM development program, which is crucial for the company’s future biosensing and edge-intelligent systems. The collaboration with Artemis Labs aims to optimize RRAM for integration at the 22nm technology node, enhancing its performance for neuromorphic and edge-AI applications. This development positions DorsaVi to capitalize on the growing edge AI market, projected to expand significantly by 2030, by providing advanced silicon solutions for wearables, robotics, and industrial safety products.
dorsaVi Limited announced the successful passing of all resolutions at its annual general meeting, including a special resolution. This development is significant for the company as it reflects shareholder support for its strategic initiatives and governance. The resolutions passed include the adoption of the remuneration report, election of a new director, and approval of performance rights and placement shares, which are crucial for the company’s operational and financial strategies moving forward.
dorsaVi Limited has acquired a groundbreaking neuromorphic technology portfolio from Technion, led by Prof. Shahar Kvatinsky. This acquisition positions dorsaVi at the forefront of next-generation robotics and wearable intelligence by integrating Processing-in-Memory (PIM) technology, which combines computation and memory into a single intelligent substrate. This strategic move transforms dorsaVi’s biosensors into autonomous nodes capable of local sensing, thinking, and acting, thereby advancing the company’s shift from reactive analytics to self-adapting edge systems. The acquisition is expected to significantly impact the global neuromorphic-computing market, which is projected to grow substantially by 2030, highlighting the rising demand for on-device intelligence.
DorsaVi Limited, a company listed on the Australian Securities Exchange, has requested a trading halt for its ordinary shares. This halt is pending an announcement related to a proposed acquisition, which is expected to be made before the commencement of normal trading on 13 November 2025. The trading halt is intended to help the company manage its continuous disclosure obligations.
dorsaVi Limited has announced the cessation of Andrew James Ronchi as a director of the company, effective November 1, 2025. This change in leadership involves a significant number of shares and options held by Ronchi, reflecting his substantial financial interest in the company. The announcement may impact the company’s governance structure and could have implications for its strategic direction and stakeholder relationships.
dorsaVi Limited has announced the commencement of an evaluation program to scale its oxide-based RRAM from 40 nm to a 22 nm process node. This initiative aims to achieve higher density, lower energy consumption, and faster switching speeds, enhancing the company’s positioning in the embedded non-volatile memory and AI-driven systems markets. The 22 nm evaluation is expected to significantly improve device performance, battery life, and responsiveness, which could strengthen dorsaVi’s competitive edge in the wearables and industrial safety sectors.
dorsaVi Limited has appointed Mathew Regan as the new Group Chief Executive Officer, effective November 1, 2025. Regan, with a strong background in digital health, AI, and advanced manufacturing, is expected to lead the company through a pivotal phase of growth. His previous success at Artrya Limited in reshaping AI-driven platforms and securing FDA clearances positions him well to drive dorsaVi’s global expansion and commercialization of next-generation technologies. The company is focusing on leveraging its RRAM-enabled sensor capabilities across multiple industries, with initiatives like the Reflex platform and the launch of Artemis Labs to accelerate development in robotics and human-machine interfaces.
dorsaVi Limited has initiated a process to engage with semiconductor development partners to explore scaling down its oxide-based Resistive Random-Access Memory (RRAM) technology to the 22 nm process node. This move aims to enhance the technology’s density, speed, and power efficiency, crucial for next-generation edge and wearable computing systems. The 22 nm node is recognized for its manufacturability and performance, providing a solid foundation for dorsaVi’s adaptive RRAM arrays in applications such as biosensing and robotics, where low latency and independence from cloud computing are essential. The company plans to establish a joint evaluation plan with selected partners to guide future developments and potential foundry engagement, marking a significant step in advancing their sensor and robotics products into more intelligent systems.
dorsaVi Limited has made significant strides in its RRAM sensor technology, initiating comprehensive testing in Singapore for biomedical applications such as electromyography and electrocardiography. The company has also signed a five-year sales agreement with a major U.S. physical therapy franchise, indicating strong market expansion potential. Additionally, dorsaVi’s ViMove+ product is showing promising growth in the U.S. market, with acquisition trends significantly higher than historical rates. The company’s financial position has strengthened with a cash balance increase, supported by a successful $5.0 million placement to accelerate RRAM and robotics technology development.
dorsaVi Limited has announced a proposed issue of 2,342,009 ordinary fully paid securities, with an expected issue date of December 3, 2025. This move aims to strengthen the company’s financial position and potentially enhance its market presence, offering significant implications for its stakeholders and industry positioning.
dorsaVi Limited has announced a proposed issue of 24 million performance rights, with the issue date set for December 3, 2025. This move is part of a placement or other type of issue, indicating a strategic effort to potentially raise capital or incentivize stakeholders, which could impact the company’s operations and market positioning within the health technology sector.
dorsaVi Limited has announced its 2025 Annual General Meeting scheduled for November 26, 2025, in Melbourne. Shareholders are encouraged to vote by proxy due to potential changes in meeting conditions, and the company emphasizes digital access to meeting documents to streamline communication and ensure shareholder engagement.
dorsaVi Limited has announced its upcoming Annual General Meeting scheduled for November 26, 2025, in Melbourne. Key agenda items include the adoption of the Remuneration Report, the election of Mr. Leigh Travers as a Director, and the approval of issuing Performance Rights to Mr. Mathew Regan. These resolutions, if passed, could influence the company’s governance structure and executive compensation, potentially impacting its strategic direction and stakeholder relations.
dorsaVi Limited has announced the cessation of 1,412,303 securities due to the expiry of options or other convertible securities without exercise or conversion as of October 7, 2025. This announcement reflects a change in the company’s issued capital and may impact its financial structure and investor relations.
dorsaVi Limited has announced its 2025 Annual General Meeting, scheduled for November 26, 2025, with nominations for director positions closing on October 15, 2025. This meeting is a significant event for the company, providing an opportunity for stakeholders to engage with the company’s leadership and discuss strategic directions. The announcement underscores dorsaVi’s commitment to transparency and governance, potentially impacting its market positioning and stakeholder relations.
dorsaVi Limited has reported significant growth in the US Physical Therapy market with its ViMove+ product, achieving a 15-fold increase in monthly acquisition trends. The company’s strategic expansion, including successful face-to-face training sessions in Arizona, has resulted in a 90% conversion rate, indicating strong demand and validating their rollout strategy. This growth is supported by the adoption of their products by US surgeons and the development of a hardware roadmap incorporating advanced technology, positioning dorsaVi for continued success in a lucrative and expanding market.
dorsaVi Limited has announced a significant technical breakthrough with its RRAM Reflex Platform, which has demonstrated superior efficiency and speed compared to state-of-the-art digital edge AI systems. The platform achieves sub-microsecond reflex latency and nanojoule-level energy use, positioning it as a transformative technology for next-generation robotics and biomedical systems, with implications for improved stability and efficiency in real-world applications.
dorsaVi Limited has updated its corporate governance statement for the financial year ending June 30, 2025, in compliance with ASX Listing Rules. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations. By providing a detailed account of its governance practices, dorsaVi aims to ensure transparency and accountability to its stakeholders, reinforcing its commitment to high standards of corporate governance.
DorsaVi Limited has released its annual report for the year ending June 30, 2025. The report highlights the company’s continued commitment to leveraging its wearable sensor technology to enhance clinical and workplace safety outcomes. Listed on the Australian Securities Exchange, DorsaVi’s strategic focus remains on expanding its market presence and improving operational efficiencies, which could have positive implications for stakeholders and strengthen its position within the health technology industry.
dorsaVi Limited has announced that Starfish Technology Fund II Nominees B Pty Ltd, HV Lodge LLC, and Mantra Secondary Opportunities II SCA-SIF have ceased to be substantial holders in the company as of August 28, 2025. This change is attributed to the dilution of shares due to issuances, affecting over 48 million fully paid ordinary shares, which may impact the company’s shareholder structure and influence in the market.
Starfish Technology Fund II Nominees A Pty Ltd and Perpetual Trustee Company Limited have ceased to be substantial holders in dorsaVi Limited as of August 28, 2025. This change is primarily due to the dilution of shares resulting from new share issuances, affecting a total of 48,763,230 fully paid ordinary shares. This development may impact dorsaVi’s shareholder structure, potentially influencing its market strategy and stakeholder relationships.
dorsaVi Limited has announced a significant technical milestone with the successful engineering validation of its RRAM-powered Reflex Platform. This platform is capable of executing neural reflex decisions in less than 0.8 microseconds with ultra-efficient energy consumption, marking a critical advancement in robotics and biomedical applications. The validation confirms that the memory element is no longer a bottleneck, shifting focus to peripheral components, and positions dorsaVi as a potential leader in the industry.
dorsaVi has announced a five-year sales agreement with Select Medical, a leading US-based network of outpatient physical therapy centers, to offer its FDA-approved products across over 1,900 locations. This partnership follows an 18-month development pilot that ensured the technology met therapists’ needs, focusing on rehabilitation and return-to-play assessments for injured athletes. The agreement marks a significant opportunity for dorsaVi to enhance its presence in the US market, potentially impacting patient assessment and rehabilitation practices.
dorsaVi Limited has announced a proposed issue of 2,000,000 unlisted performance rights, with the issue date set for November 4, 2025. This move is part of a placement or other type of issue, which may impact the company’s market positioning and stakeholder interests by potentially enhancing its financial flexibility and growth opportunities.
dorsaVi Limited has appointed Ed Doller, a veteran in the semiconductor industry, as a Strategic Adviser to guide the company through its transition into advanced technologies such as RRAM-enabled systems and edge AI. This strategic move is part of dorsaVi’s broader plan to expand its technological capabilities and market reach, with a focus on real-time biomedical sensing and autonomous motion platforms, potentially positioning the company as a leader in ultra-low power edge AI applications.